The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, but its legacy within the broader market now presents questions about potential gains. Copycat versions are undercutting market share, causing concerns that betting on companies heavily reliant to Viagra's previous influence could be a problematic move , especial